Table 1 Patient characteristics

HCV genotype

  Genotype 1a/b/other

2/11/0 (9.1/50.0/0)

24/18/1 (35.8/26.9/1.5)

23/16/3 (28.4/19.8/3.7)

28/29/3 (24.1/25.0/2.6)

36/52/4 (19.9/28.7/2.2)

31/19/0 (31.0/19.0/0.0)

  Genotype 2

2 (9.1)

9 (13.4)

6 (7.4)

5 (4.3)

10 (5.5)

2 (2.0)

  Genotype 3

3 (13.6)

11 (16.4)

20 (24.7)

31 (26.7)

56 (28.7)

25 (25.0)

  Genotype 4

4 (18.2)

3 (4.5)

7 (8.6)

14 (12.1)

10 (5.5)

7 (7.0)

 Genotype 5/6

0 (0)

0 (0)

1 (1.2)

0 (0)

1 (0.6)

0 (0)

 Unkown

0 (0)

1 (1.5)

5 (6.2)

6 (5.2)

12 (6.6)

16 (7.0)

Liver cirrhosis

11 (50.0)

12 (17.9)

11 (13.6)

23 (19.8)

37 (20.4)

24 (24.0)

 Child Pugh A

9 (81.8)

10 (83.3)

8 (72.7)

19 (82.6)

29 (78.4)

19 (79.2)

 Child Pugh B/C

0 (0)

1 (8.3)

2 (18.2)

3 (13.0)

5 (13.5)

4 (16.7)

 Unknown

2 (18.2)

1 (8.3)

1 (9.1)

1 (4.3)

3 (8.1)

1 (4.2)

Comorbidities

 Chronic kidney disease

1 (4.5)

2 (1.5)

0 (0)

3 (2.6)

1 (0.6)

0 (0)

Treatment status

 Treatment naïve

8 (36.4)

45 (67.2)

46 (63.0)

92 (79.3)

150 (82.9)

83 (83.0)

 PEG-IFN-experienced

13 (59.1)

18 (26.9)

23 (31.5)

15 (12.9)

20 (11.0)

12 (12.0)

 DAA-experienced

1 (4.5)

4 (6.0)

4 (5.5)

9 (7.8)

11 (6.1)

5 (5.0)

 DAA regimen

  ELB/GRZ

-

-

5 (6.2)

11 (9.5)

29 (16.0)

8 (8.0)

  GLE/PIB

-

-

-

46 (39.7)

76 (42.0)

69 (69.0)

  OMV/PTV/RTV + DSV

5 (22.7)

7 (10.4)

3 (3.7)

-

-

-

  SOF

4 (18.2) 

2 (3.0)

-

1 (0.9)

-

-

  SOF/DCV

7 (31.8)

27 (40.3)

25 (30.9)

6 (5.2)

-

-

  SOF/LDV

4 (18.2)

30 (44.8)

32 (39.5)

15 (12.9)

2 (1.1)

-

  SOF/SIM

2 (9.1)

-

1 (1.2)

-

-

-

 SOF/VEL

-

-

14 (17.3)

39 (29.3)

61 (33.7)

19 (19.0)

 SOF/VEL/VOX

-

-

1 (1.2)

1 (0.9)

12 (6.6)

3 (3.0)

 SOF + GLE/PIB

-

-

-

2 (1.7)

-

1 (1.0)

 Other

-

1 (1.5)

-

-

1 (0.6)

-

Addition ribavirin

14 (63.6)

10 (14.9)

8 (9.9)

2 (1.7)

4 (2.2)

3 (3.0)

SVR

21 (95.5)

64 (95.5)

78 (96.3)

113 (97.4)

173 (96.6)

93 (93.0)